Payment overview · 2025
General Payments
$176.64
8 reported records · 7 companies
Healthcare provider profile · identity verified
Debbie Ann Sprague, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · PENSACOLA, FL · NPI 1497260400
Verified facts
What the public records show
CMS Open Payments records show Debbie Ann Sprague, ARNP received $176.64 in general payments during 2025 across 8 reported records.
PFIZER INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.70 | 19.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.98 | 17.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.28 | 16.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.82 | 14.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.98 | 13.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.74 | 10.6% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $15.14 | 8.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $176.64 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $29.98 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.28 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 43 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 432 | 148 |
| Losartan Potassium | Losartan Potassium | 406 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 80 |
| Omeprazole | Omeprazole | 199 | 71 |
| Lisinopril | Lisinopril | 153 | 61 |
| Sertraline Hcl | Sertraline Hcl | 148 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 49 |
| Furosemide | Furosemide | 132 | 49 |
| Trazodone Hcl | Trazodone Hcl | 130 | 41 |
| Tramadol Hcl | Tramadol Hcl | 128 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 31 |
| Gabapentin | Gabapentin | 111 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 51 |
| Alprazolam | Alprazolam | 103 | 30 |
| Azithromycin | Azithromycin | 102 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 29 |
| Montelukast Sodium | Montelukast Sodium | 96 | 36 |
| Carvedilol | Carvedilol | 91 | 35 |
| Ozempic | Semaglutide | 89 | 27 |
| Buspirone Hcl | Buspirone Hcl | 88 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 27 |
| Ezetimibe | Ezetimibe | 78 | 34 |
| Metformin Hcl | Metformin Hcl | 76 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 72 | 63 |
| Prednisone | Prednisone | 72 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 35 |
| Potassium Chloride | Potassium Chloride | 67 | 33 |
| Meloxicam | Meloxicam | 64 | 26 |
| Jardiance | Empagliflozin | 63 | 24 |
| Allopurinol | Allopurinol | 62 | 21 |
| Bupropion Xl | Bupropion Hcl | 61 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 23 |
| Synthroid | Levothyroxine Sodium | 60 | 13 |
| Glimepiride | Glimepiride | 58 | 19 |
| Mounjaro | Tirzepatide | 58 | 14 |
| Metformin Hcl Er | Metformin Hcl | 54 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 24 |
| Famotidine | Famotidine | 49 | 21 |
| Methylprednisolone | Methylprednisolone | 45 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 16 |
| Eliquis | Apixaban | 43 | 11 |
| Lorazepam | Lorazepam | 43 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Mirtazapine | Mirtazapine | 41 | 15 |
| Simvastatin | Simvastatin | 41 | 13 |
| Fluconazole | Fluconazole | 40 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 19 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 15 |
| Trulicity | Dulaglutide | 37 | 13 |
| Alendronate Sodium | Alendronate Sodium | 36 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 35 | suppressed |
| Telmisartan | Telmisartan | 34 | 11 |
| Cephalexin | Cephalexin | 33 | 28 |
| Promethazine Hcl | Promethazine Hcl | 33 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 12 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 25 |
| Atenolol | Atenolol | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | 11 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Nystatin | Nystatin | 27 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Finasteride | Finasteride | 24 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Ofloxacin | Ofloxacin | 23 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | 14 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $176.64 · 8 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, ETERNA, EVENITY, JARDIANCE, NURTEC ODT, PREVNAR 20, QUTENZA, SHINGRIX, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error